Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Acq. announced
Director departure
Inv. presentation
Quarterly results
Consulting agrmnt
Appointed COO
Appointed director
CC transcript
|
|
BIOGEN INC. (BIIB)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 04/28/2021 |
GN
| Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI® (natalizumab) |
| 04/28/2021 |
GN
| Biogen Releases 2020 Year in Review Demonstrating Its Commitment to Transparency and Progress across Environmental, Social and Governance Metrics |
| 04/19/2021 |
GN
| Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients |
| 04/07/2021 |
GN
| The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat Relapsing-Remitting Multiple Sclerosis |
| 03/04/2021 |
GN
| Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina |
| 02/24/2021 |
GN
| Life Science Cares and Biogen Foundation Help Launch Food For Free's Just Eats Program |
| 02/11/2021 |
GN
| Biogen Announces the Expiration Date Results of Its Cash Tender Offer |
| 02/11/2021 |
GN
| Biogen and LabCentral Award Two Golden Tickets to Local and Innovative Science Startups |
| 02/10/2021 |
GN
| Biogen Announces the Pricing Terms of its Cash Tender Offer |
| 02/10/2021 |
GN
| Biogen Announces the Pricing Terms of Its Private Exchange Offer |
| 02/04/2021 |
GN
| Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045 Open to Certain Holders Only |
| 02/01/2021 |
GN
| Biogen Announces FDA Approval of PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis |
| 01/29/2021 |
GN
| Biogen and Eisai Announce FDA's 3-Month Extension of Review Period for the Biologics License Application for Aducanumab |
| 01/11/2021 |
GN
| BIIB FILING DEADLINE TOMORROW: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biogen Inc. |
| 01/11/2021 |
GN
| DEADLINE ALERT for TILE, BABA, and BIIB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders |
| 01/11/2021 |
GN
| Portnoy Law: Lawsuit Filed On Behalf of Biogen, Inc. Investors |
| 01/11/2021 |
GN
| Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone |
| 01/08/2021 |
GN
| DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Biogen, Inc. and Encourages Investors to Contact the Firm |
| 01/08/2021 |
GN
| Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec) |
| 01/06/2021 |
GN
| TILE, BIIB & BABA Upcoming Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Encourages Investors to Contact the Firm |
| 01/05/2021 |
GN
| BIIB INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biogen Inc. |
| 01/05/2021 |
GN
| ViGeneron signs global collaboration agreement for ophthalmic gene therapy development |
| 01/04/2021 |
GN
| DEADLINE ALERT for TILE, BABA, and BIIB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders |
| 12/29/2020 |
GN
| Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Interface, Cabot Oil & Gas, Biogen, and Stride and Encourages Investors to Contact the Firm |
| 12/29/2020 |
GN
| DEADLINE ALERT for BABA, BIIB, YY, LRN: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders |
| 12/28/2020 |
GN
| Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen, Inc. (BIIB) |
| 12/28/2020 |
GN
| TILE, BIIB & BABA Class Actions: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm |
| 12/22/2020 |
GN
| Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Stride, JOYY, and Berry Corporation and Encourages Investors to Contact the Firm |
| 12/22/2020 |
GN
| ROSEN, A TOP RANKED LAW FIRM, Reminds Biogen Inc. Investors of Important January 12 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourages Investors with Losses in Excess of $1 Million to Contact the Firm – BIIB |
| 12/22/2020 |
GN
| DEADLINE ALERT for TILE, BABA, and BIIB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders |
| 12/21/2020 |
GN
| The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis |
| 12/20/2020 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB |
| 12/17/2020 |
GN
| DEADLINE ALERT for TILE, BABA, and BIIB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders |
| 12/16/2020 |
GN
| Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cabot Oil & Gas, Biogen, JOYY, and Berry Corporation and Encourages Investors to Contact the Firm |
|
|
|